Dimensional Fund Advisors LP grew its position in shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 419.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 647,187 shares of the biopharmaceutical company’s stock after acquiring an additional 522,565 shares during the quarter. Dimensional Fund Advisors LP owned about 1.49% of Intra-Cellular Therapies worth $8,038,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Federated Investors Inc. PA increased its stake in Intra-Cellular Therapies by 113.3% during the second quarter. Federated Investors Inc. PA now owns 183,035 shares of the biopharmaceutical company’s stock worth $2,273,000 after acquiring an additional 97,228 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in Intra-Cellular Therapies by 5.6% during the first quarter. Schwab Charles Investment Management Inc. now owns 137,975 shares of the biopharmaceutical company’s stock worth $2,243,000 after acquiring an additional 7,335 shares during the last quarter. Vanguard Group Inc. increased its stake in Intra-Cellular Therapies by 7.3% during the first quarter. Vanguard Group Inc. now owns 2,741,887 shares of the biopharmaceutical company’s stock worth $44,556,000 after acquiring an additional 186,165 shares during the last quarter. BB Biotech AG increased its stake in Intra-Cellular Therapies by 11.7% during the second quarter. BB Biotech AG now owns 2,150,000 shares of the biopharmaceutical company’s stock worth $26,703,000 after acquiring an additional 225,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Intra-Cellular Therapies by 59.9% during the first quarter. Goldman Sachs Group Inc. now owns 133,184 shares of the biopharmaceutical company’s stock worth $2,164,000 after acquiring an additional 49,884 shares during the last quarter. Institutional investors own 59.55% of the company’s stock.
ITCI has been the subject of several research analyst reports. BTIG Research restated a “buy” rating and set a $36.00 price target on shares of Intra-Cellular Therapies in a research note on Friday, September 8th. Piper Jaffray Companies upgraded Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $14.00 to $33.00 in a research note on Thursday, September 7th. SunTrust Banks, Inc. restated a “hold” rating and set a $22.00 price target (up from $16.00) on shares of Intra-Cellular Therapies in a research note on Friday, September 8th. Leerink Swann upgraded Intra-Cellular Therapies from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 23rd. Finally, Cowen and Company reiterated an “outperform” rating and issued a $27.00 target price (up previously from $20.00) on shares of Intra-Cellular Therapies in a research note on Friday, September 8th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $25.00.
Shares of Intra-Cellular Therapies Inc. (NASDAQ ITCI) opened at $15.32 on Friday. Intra-Cellular Therapies Inc. has a 12 month low of $7.85 and a 12 month high of $22.67.
Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.53). Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.06 million. During the same quarter last year, the firm earned ($0.70) earnings per share. The company’s revenue for the quarter was up 675.0% compared to the same quarter last year. analysts expect that Intra-Cellular Therapies Inc. will post -2.16 EPS for the current fiscal year.
In other Intra-Cellular Therapies news, CEO Sharon Mates sold 18,750 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $15.75, for a total transaction of $295,312.50. Following the completion of the sale, the chief executive officer now owns 1,107,457 shares in the company, valued at approximately $17,442,447.75. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Alafi Capital Co Llc acquired 258,065 shares of the stock in a transaction on Monday, October 2nd. The shares were acquired at an average price of $15.50 per share, with a total value of $4,000,007.50. Following the purchase, the insider now owns 3,953,270 shares in the company, valued at $61,275,685. The disclosure for this purchase can be found here. 19.80% of the stock is currently owned by company insiders.
WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/11/19/intra-cellular-therapies-inc-itci-shares-bought-by-dimensional-fund-advisors-lp.html.
Intra-Cellular Therapies Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc. (NASDAQ:ITCI).
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.